Institut für Transfusionsmedizin und Immunhämatologie
Univ.-Prof. Dr. med. Halvard B. Bönig, M.A.
Arzt für Kinderheilkunde und Jugendmedizin, Arzt für Transfusionsmedizin

Abteilung
Forschung und Entwicklung – Translationale Zelltherapeutikaentwicklung

Beruflicher Werdegang

1989-1996
Studium der Anglistik, Kunstgeschichte und Medizin an der Heinrich-Heine-Universität Düsseldorf, St. Bartholomew’s Hospital Medical School, London, und University of Tennessee, Memphis TN
 
1995
Magister Artium Anglistik und Kunstgeschichte
 
1996
Med. Staatsexamen
 
1998
Promotion zum Dr. med. an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf
 
1997-2002
Wissenschaftlicher Mitarbeiter (Arzt in der Weiterbildung) am Zentrum für Kinderheilkunde und Jugendmedizin der HHU Düsseldorf; Facharztprüfung zum Arzt für Kinderheilkunde und Jugendmedizin
 
2002-2004
Senior Research Fellow im Labor von Prof. Papayannopoulou, University of Washington, Seattle, WA
 
2005-2007
Acting Assistant Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2007-2009
Wissenschaftlicher Mitarbeiter beim DRK-Blutspendedienst BaWüHe, Institut Frankfurt
 
2008
Affiliate Assistant Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2009-2013
Leiter der Abteilung für Zelltherapeutika / Cell Processing (GMP), Institut für Transfusionsmedizin und Immunhämatologie Frankfurt a.M.
 
2011-
Affiliate Associate Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
Aktuell:
Professor (W3) für Translationale Entwicklung von Zelltherapeutika am Institut für Transfusionsmedizin und Immunhämatologie, Fachbereich Medizin, Johann-Wolfgang-Goethe Universität, Frankfurt Leiter Herstellung Experimentelle Zelltherapeutika und Sachkundige Person, DRK-Blutspendedienst BaWüHe, Institut Frankfurt
 

Mitgliedschaften in wissenschaftlichen Fachgesellschaften (ausgewählt)

  • American Society of Hematology
  • International Society of Experimental Hematology
  • American Association of Blood Banks
  • International Society of Blood Transfusion
     
  • Associate Member Faculty of 1000 (f1000) Hematology

Ausgewählte Publikationen (seit 2009)

  • 38. Bonig H, Priestley G, Wohlfahrt ME, Kiem HP, Papayannopoulou T (2009) Blockade of alpha6-integrin reveals diversity in homing patterns between human, non-human primate and murine cells, Stem Cells Dev 18:839-44
  • 39. Bonig H, Chudziak D, Priestley G, Papayannopoulou T (2009) Insights into the biology of mobilized hematopoietic stem/progenitor cells (HSPC) through innovative treatment schedules of the CXCR4 antagonist AMD3100, Exp Hematol 37:402-415
  • 40. Chudziak D*, Sireis W*, Pfeiffer H-U, Henschler R, Seifried E, Bonig H (2009) Accumulation of soluble inflammatory mediators between blood donation and prestorage leukocyte depletion, Vox Sanguinis 96:163-166        *contributed equally
  • 41. Bonig H, Watts K, Chang KH, Kiem HP, Papayannopoulou T (2009) Concurrent blockade of α4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization, Stem Cells 27:836-837
  • 42. Jiang Y, Bonig H, Ulyanova T, Chang KH, Papayannopoulou T (2009) On the adaptation of endosteal stem cell niche function in response to stress, Blood 114:3773-82
  • 43. Bader P, Willasch A, Jarisch A, Soerensen J, Esser R, Bonig H, Klingebiel T (2010) Transplantation CD3/CD19-depletierter Stammzellen - Plattform für weiterführende Zelltherapie, Klin Padiatr 158:216-222
  • 44. Bonig H and Papayannopoulou T (2010) Vagrant stem cells and their gene companions, Cell Stem Cell 7:547-8
  • 45. Reinhardt P*, Brauninger S*, Bialleck H, Thorausch K, Smith R, Schrezenmeier H, Seifried E, Wiesneth M, Bonig H(2011) Automatic interphase-controlled apheresis collection of stem/progenitor cells: Results from an autologous donor validation trial of a novel stem cell apheresis device, Transfusion 51:1321-30      *contributed equally
  • 46. Dauber K*, Becker D*, Odendahl M, Seifried E, Bonig H*, Tonn T* (2011) Enumeration of viable CD34+ cells by flow cytometry in blood, bone marrow and cord blood: Results of the validation study of the novel BDTM Stem Cell Enumeration Kit, Cytotherapy 13:449-58         *contributed equally
  • 47. Spohn G, Geisen C, Luxembourg B, Seifried E, Bonig H (2011) Development and validation of a fast and reliable test for pharmacogenetics of vitamin-K antagonist dosing, Mol Diagn Ther 15:13-9
  • 48. Brauninger S, Thorausch K, Bialleck H, Seifried E, Bonig H (2011) Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v.5.0, a novel, automatic interphase-controlled apheresis system, Vox sanguinis 101:237-46
  • 49. Bonig H, Muller M (2011) Donor safety comes first, Vox sanguinis 101:175
  • 50. Brauninger S, Bialleck H, Seifried E, Bonig H (2011) Asystole during stem cell apheresis in a young healthy female volunteer donor, Transfusion 51:1594
  • 51. Bonig H, Heiden M, Schüttrumpf J, Müller MM, Seifried E (2011) Potenzial hämatopoietischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien, Bundesgesundheitsanzeiger 54:791-796
  • 52. Rosskopf K, Ragg SJ, Worel N, Grommé M, Preijers F, Braakman E, Schuurhuis GJ, van Riet I, Wendel S, Fontão-Wendel R, Lazar A, Goldman M, Halpenny M, Giulivi A, Letcher B, McGann L, Korhonen M, Humpe A, Wiesneth M, Schauwecker P, Schrezenmeier H, Bonig H, Henschler R, Seifried E, Accorsi P, Bonfini T, Takanashi M, van Beckhoven JM, Brand A, Gounder D, Wong A, Dooccey A, Forrest E, Galea G, Smythe J, Pawson R, Reems JA, Oh J, Reesink HW, Panzer S (2011) Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow) Vox Sanguinis 101:255-75
  • 53. Kuci Z, Kuci S, Zircher S, Koller S, Schubert R, Lieberz R, Bonig H, Klingebiel T, Bader P (2011) Immunomodulatory properties of multipotent mesenchymal stromal cells derived from CD271+ bone marrow mononuclear cells, Cytotherapy 13:1193-204
  • 54. Chang KH, Bonig H, Papayannopoulou T (2011) Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells: an overview. Stem Cells International 2011:791604
  • 55. Ohtani K, Vlachonjannis GJ, Koyanagi M, Boeckel JN, Urbich C, Farcas R, Bonig H, Marquez VE, Zeiher AM, Dimmeler S (2011) Epigenetic repression of endothelial lineage committed genes in pro-angiogenic hematopoietic progenitor cells. Circ Res 109:1219-29
  • 56. Bader P, Soerensen J, Jarisch A, Ponstingl E, Krenn T, Faber J, Dürken M, Reinhardt H, Willasch A, Esser R, Bonig H, Koehl U, Klingebiel T (2011) Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin Haematol. 24:331-7
  • 57. Brauninger S, Bialleck H, Thorausch K, Felt T, Seifried E, Bonig H (2012) Allogeneic donor peripheral blood “stem cell” apheresis: Prospective comparison of two apheresis systems, Transfusion 52:1137-45
  • 58. Cummerow C, Schwind P, Spicher T, Geisen C, Seifried E, Bonig H (2012) Apheresis product identification in the transplant center: Development of point-of-care protocols for extended blood typing of stem cell apheresis products. Bone Marrow Transplantation 47:860-5
  • 59. Rupp S, Jux C, Bonig H, Bauer J, Tonn T, Wossmann W, Seifried E, Dimmeler S, Zeiher AM, Schranz D (2012) Intracoronary bone marrow cell application for terminal heart failure in children. Cardiology in the Young 22:558-63
  • 60. Chang HK, Fang X, Wang H, Huang A, Cao H, Yang Y, Bonig H, Papayannopoulou T (2012) Epigenetic modifications and chromosome conformations of the beta globin locus are conserved throughout development in relation to globin expression. Stem Cell Reviews and Reports (in press)
  • 61. Bonig H, Schmidt M, Hourfar K, Schüttrumpf J, Seifried E (2012) Sufficient blood, safe blood: Can we have both? BMC Medicine 23;10:29
  • 62. Bonig H and Papayannopoulou T (2012) Mobilization of hematopoietic stem/progenitor cells: General principles and molecular mechanisms; in: Kolonin M and Simmons P (eds.): Methods in Molecular Biology 904 - stem cell mobilization, 904:1-14 Humana Press, New York, NY.
  • 63. Rettinger E, Meyer V, Kreyenberg H, Volk A, Kuci S, Willasch A, Koscielniak E,  Fulda S, Wels W, Bonig H, Klingebiel T, Bader B (2012) Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front. Oncol. - Pediatric Oncology 2:32
  • 64. Bonig H and Kim YM (2012) VLA4 in Acute Lymphoblastic Leukemia; in: Andreeff, M (ed.): Targeted Therapy of Acute myeloid Leukemias, Springer, New York, NY (in press)
  • 65. Muller MM, Bialleck H, Bohmke B, Brauninger S, Varga C, Seidl C, Seifried E, Tonn T, Bonig H (2013) Safety of healthy volunteer stem cell mobilization with Filgrastim G-CSF: Results of a prospective longitudinal five-year follow-up study. Vox Sanguinis 104:46-54
  • 66. Sörensen J, Jarisch A, Smorta C, Köhl U, Bader P, Seifried E, Bonig H (2013) Pediatric apheresis with a novel apheresis device with electronic interface control. Transfusion 53:761-5
  • 67. Bonig H and Papayannopoulou Th (2013) Hematopoietic stem cell mobilization: Updated conceptual renditions. Leukemia 27:24-31
  • 68. Eichler H, Schrezenmeier H, Schallmoser K, Strunk D, Nystedt J, Kaartinen T, Korhonen M, Fleury-Cappellesso S, Sensebé L, Bönig H, Rebulla P, Giordano R, Lecchi L, Takanashi M, Watt SM, Austin EB, Guttridge M, McLaughlin LS, Panzer S, Reesink HW (2013) Donor selection and release criteria of cellular therapy products. Vox Sang. 104:67-91
  • 69. Tramsen L, Schmidt S, Bonig H, Latge Jean-Paul, Lass-Flörl C, Roeger F, Seifried E, Klingebiel T, Lehrnbecher T (2013) Clinical-scale generation of multispecific antifungal T-cells targeting candida, aspergillus and mucormycetes. Cytotherapy 15:344-51
  • 70. Hsieh YT*, Gang EJ*, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Syedmedi S, Klemm L, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bonig H*, Kim YM* (2013) VLA4 blockade eradicates drug resistant pre-B acute lymphoblastic leukemia. Blood 121:1814-8    *equal contribution
    Featured in Newswatch, Cancer Discovery January 24, 2013, DOI: 10.1158/2159-8290.CD-RW2013-019
  • 71. Schulz M, Bug G, Bialleck H, Serve H, Seifried E, Bonig H (2013) Leukodepletion for hyperleukocytosis – first report on a novel technology featuring electronic interphase management. Vox Sanguinis 105:47-53
  • 72. Thorausch K, Schulz M, Bialleck H, Luxembourg B, Seifried E, Bonig H (2013) Feasibility and efficacy of granulocyte apheresis with Spectra Optia IDL. Transfusion 2013 Apr 15. doi: 10.1111/trf.12197. [Epub ahead of print]
  • 73. Rettinger E, Bonig H, Wehner S, Lucchini G, Willasch A, Jarisch A, Soerensen J, Esser R, Rossig C, Klingebiel T, Bader P (2013) Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant. 48:1141-3
  • 74. Büchner S, Sliva K, Bonig H, Voelker I, Waibler Z, Kirberg H, Schnierle B (2013) Delayed onset of graft versus host disease in immunodeficent HLA-DQ8 transgenic, murine MHC class II deficient mice repopulated by human peripheral blood mononuclear cells. Clinical and Experimental Immunology 173:355-64
  • 75. Karpova D, Wiercinska E, Bonig H (2013) Mobilisierung hämatopoietischer Stammzellen [Mobilization of hematopoietic stem cells]. Transfusionsmedizin (in press)
  • 76. Kuci Z, Seiberth J, Latifi-Pupovci H, Wehner S, Stein S, Grez M, Bonig H, Köhl U, Klingebiel T, Bader P, Kuci S (2013) Clonal Analysis of Multipotent Stromal Cells Derived from CD271+ Bone Marrow Mononuclear Cells: Functional Heterogeneity and Different Mechanisms of Allosuppression. Hematologica 98:1609-1616
  • 77. Koeberle V, Pleli T, Schmithals C, Augusto EA, Haupenthal J Bonig H, Peveling-Oberhag J, Miondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A (2013) Cell-free circulating vesicle-associated miRNAs are more stable and more resistant to RNase A treatment than non-vesicle cell-free circulating miRNAs. PLOS ONE 20;8:e75184
  • 78. Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit AR, Levesque JP, Romagnoli B, Patel K, Chevalier E, Dembowsky K, Bonig H (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 2013 Sep 12. doi: 10.1038/leu.2013.266. [Epub ahead of print]
  • 79. Hahn S, Sireis W, Hourfar K, Karpova D, Dauber K, Kempf VAJ, Seifried E, Schmidt M, Bonig H (2013) Effects of storage temperature on hematopoietic stability and microbial safety of bone marrow aspirates. Bone Marrow Transplant. (in press)
  • 80. Schulz M, Bialleck H, Thorausch K, Bug G, Dunzinger U, Seifried E, Bonig H (2013) Unstimulated leukoapheresis in patients and donors – comparison of two apheresis systems. Transfusion (in press)

(zuletzt aktualisiert 30.10.2013)

Univ.-Prof. Dr. med. Halvard B. Bönig, MA

Univ.-Prof. Dr. med. Halvard B. Bönig, MA
Professur für Translationale Entwicklung von Zelltherapeutika

Institut für Transfusionsmedizin und Immunhämatologie Fachbereich Medizin,
Johann-Wolfgang-Goethe Universität
und DRK-Blutspendedienst Baden-Württemberg-Hessen,
Institut Frankfurt am Main
Sandhofstrasse 1
60528 Frankfurt
Tel.: 069 / 6782-177

E-Mail: